The new face of British Biotech

OXFORD - Elliot Goldstein, the new CEO at British Biotech plc, has wasted no time stamping his mark on the company. Within six weeks of taking up arguably the most challenging job in European biotech, Goldstein has wiped away more than 10 years of corporate ambition by abandoning the fully integrated pharmaceutical company (FIPCO) business model for a more conservative partnering strategy.

He also is leading the charge to shake up the clinical programs at British Biotech (LSE:BBG, BBIOY, Oxford, U.K.)...